Importantly, ctDNA fluctuations were monitored using the OncomineTM Breast cfDNA assay to test whether biomarkers may change rapidly between chemotherapy and aromatase inhibitor (AI) treatment in the setting of advanced breast cancer, potentially reflecting disease dynamics. The gene discussed is CYP19A1; the disease is breast carcinoma.